David Gerber, MD

David Gerber, MD discusses treating Lambert-Eaton Myasthenic Syndrome in patients with small-cell lung cancer based on updated guidelines.

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

David Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

An oncologist reviews the case of a 57-year-old man diagnosed with small cell lung cancer after Lambert-Eaton myasthenic syndrome.

Drs. Steven Vernino and David Gerber continue their conversation on their preferred treatment approaches and monitoring strategies for Lambert-Eaton myasthenic syndrome and small cell lung cancer.

Key opinion leaders detail the treatment options available for Lambert-Eaton myasthenic syndrome.

Steven Vernino, MD, describes the first-line treatment options for small cell lung cancer with Lambert-Eaton myasthenic syndrome.

Drs. David Gerber and Steven Vernino review the case of a 64-year-old man with Lambert-Eaton myasthenic syndrome.

Two experts debate the preferred testing options for Lambert-Eaton myasthenic syndrome presenting with small cell lung cancer.

A neurologist explains how to test for and diagnose Lambert-Eaton myasthenic syndrome.

David Gerber, MD, and Steven Vernino, MD, PhD, provide an overview of Lambert-Eaton myasthenic syndrome and its association with cancers.

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.